ClinicalTrials.gg
CompletedNCT07404657Updated Oct 22, 2026

Preliminary Assessment of an Automated Tool for Diabetic Retinopathy Screening

An observational study in Diabetic Retinopathy (DR), sponsored by Centervue SpA. Completed at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Centervue SpA · Observational

How we know

Updated Oct 22, 2026Now CompletedFirst site in United States+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
198
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 54 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Enrollment
31st of 70
198 · median 161
Started
2026
with 18 others
Observational
70 of 267
8 open now
Registered
253rd of 267
by date

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 31st largest by enrollment of the 70 observational ones that give a count, is one of 19 that started in 2026, is one of 70 observational ones, and was the 253rd registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

This study is being done to evaluate the performance of a software that uses artificial intelligence to analyze photographs of the retina to help detect diabetic retinopathy. The study will also assess the safety of the software in combination with a fundus camera already available on the market. This software analyzes retinal photographs to detect more than mild diabetic retinopathy in adults with diabetes. The results will be compared to expert human evaluations.

03

Conditions studied

  • Diabetic Retinopathy (DR)

Browse trials for

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

population attending a primary-care facility with diagnosis of diabetes mellitus and/or past diagnosis of diabetic retinopathy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 22 years old or older
  • diabetes or diabetic retinopathy
  • understand the study information and able to sign a consent form

Exclusion criteria

Exclusion Criteria:

  • cannot tolerate eye imaging tests
  • laser treatment or injections
  • eye surgery, except for simple cataract surgery
  • currently involved in another study
  • pregnant
  • cannot or do not want to have your eyes dilated
  • photodynamic therapy within the last 90 days
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
198 participants (actual)
Patient registry
No

Interventions

  • Deviceautomatic analysis of fundus images performed by the software tool based on artificial intelligence

    the duration of the intervention is the analysis performed by the software tool based on fundus images acquired

06

What researchers measure

Primary outcomes

  1. Number of subjects whose results provided by the automatic AI-based tool match the reading center grading for the identification of referable diabetic eye disease (more than mild DR).

    Time frame: 1-day visit

Secondary outcomes

  1. percentage of eyes for which the AI-based automatic tool produced a result

    Time frame: 1-day visit

07

Study locations

1 site
  • Rovia University - Jacksonville (East Coast for Institute Jacksonville)
    Jacksonville, Florida 32216, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2026 to primary completion in Jun 2026, 4 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Apr 2026 → Jun 2026 and completion Apr 2026 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Feb 11, 2026
StartActual
Feb 6, 2026
Primary completionActual
Jun 17, 2026was Apr 2026
CompletionActual
Jun 17, 2026was Apr 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 22, 2026
Sites
1 site added — first site in United States
Show site
  • Rovia University - Jacksonville (East Coast for Institute Jacksonville) · Jacksonville, United States
Oct 22, 2026
Primary completion
Apr 2026→Jun 17, 2026 (actual)
Oct 22, 2026
Study completion
Apr 2026→Jun 17, 2026 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Not yet recruiting→Completed
    1 site added — first site in United States
    Show site
    • Rovia University - Jacksonville (East Coast for Institute Jacksonville) · Jacksonville, United States
    Primary completion Apr 2026→Jun 17, 2026 (now actual)
    Study completion Apr 2026→Jun 17, 2026 (now actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07404657
Lead sponsor
Centervue SpA
Responsible party
Sponsor
First posted
Feb 11, 2026
Start date
Feb 6, 2026
Primary completion
Jun 17, 2026
Completion
Jun 17, 2026
Last update
Oct 22, 2026

Oversight

FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion